Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dorothea Buck

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Plos One|February 8, 2017
Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test resultsJenny Link, Ryan Ramanujam, Michael Auer, et al.
Neurology|August 9, 2013
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patientsNicholas Schwab, Tilman Schneider-Hohendorf, Vilmos Posevitz, et al.
Journal of Neuroimmunology|November 18, 2018
Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort studyPoul Erik H Jensen, Clemens Warnke, Kathleen Ingenhoven, et al.
Genetic Epidemiology|October 27, 2015
Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome ArrayTheresa Dankowski, Dorothea Buck, Till F M Andlauer, et al.
Brain : a Journal of Neurology|January 25, 2015
Genetic variants are major determinants of CSF antibody levels in multiple sclerosisAn Goris, Ine Pauwels, Marte W Gustavsen, et al.
Plos Medicine|October 30, 2020
Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortiumSigne Hässler, Delphine Bachelet, Julianne Duhaze, et al.
Nature Genetics|September 8, 2015
Class II HLA interactions modulate genetic risk for multiple sclerosisLoukas Moutsianas, Luke Jostins, Ashley H Beecham, et al.
Science Advances|July 8, 2016
Novel multiple sclerosis susceptibility loci implicated in epigenetic regulationTill F M Andlauer, Dorothea Buck, Gisela Antony, et al.
Nature Genetics|October 1, 2013
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis, Ashley H Beecham, Nikolaos A Patsopoulos, et al.
Nature|August 12, 2011
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis, , Stephen Sawcer, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Plos One|February 8, 2017
Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test resultsJenny Link, Ryan Ramanujam, Michael Auer, et al.
Neurology|August 9, 2013
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patientsNicholas Schwab, Tilman Schneider-Hohendorf, Vilmos Posevitz, et al.
Journal of Neuroimmunology|November 18, 2018
Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort studyPoul Erik H Jensen, Clemens Warnke, Kathleen Ingenhoven, et al.
Genetic Epidemiology|October 27, 2015
Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome ArrayTheresa Dankowski, Dorothea Buck, Till F M Andlauer, et al.
Brain : a Journal of Neurology|January 25, 2015
Genetic variants are major determinants of CSF antibody levels in multiple sclerosisAn Goris, Ine Pauwels, Marte W Gustavsen, et al.
Plos Medicine|October 30, 2020
Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortiumSigne Hässler, Delphine Bachelet, Julianne Duhaze, et al.
Nature Genetics|September 8, 2015
Class II HLA interactions modulate genetic risk for multiple sclerosisLoukas Moutsianas, Luke Jostins, Ashley H Beecham, et al.
Science Advances|July 8, 2016
Novel multiple sclerosis susceptibility loci implicated in epigenetic regulationTill F M Andlauer, Dorothea Buck, Gisela Antony, et al.
Nature Genetics|October 1, 2013
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis, Ashley H Beecham, Nikolaos A Patsopoulos, et al.
Nature|August 12, 2011
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis, , Stephen Sawcer, et al.
Pageof 4